February 22, 2017 7:56am
We need to drain the swamp of those who have sold investors the line; we’re here to facilitate cures that gave only dilution, greater losses and false hope
Strike a blow for investor rights against those who depreciate and dilute while maintaining huge salaries and spending with questionable advances
Anyone who reads my posts, knows that I am about making money, no matter what happens in the sector
Money ball: calling 2 strikes and 3 hits – still in the early innings
Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.
Expectation will be the word for 2017 – meeting the unknowns with the soon to be exposed concerns will be the subject of investing decisions through this year 2017.
Today’s headlights: Dow futures are DOWN -0.04% and NASDAQ futures are DOWN -0.07%
Indexes and ETFs: The IWM (-0.43%) IBB (-0.30%) are down while XBI and XLV are NOT indicating
Companies in my headlights:
BUY: ONCE, ONVO and VSTM
SELL: BLUE and BSTG
U.S. stock index futures pointed to a lower to mixed open on Wednesday morning as traders focused on a host of earnings reports after fresh record highs in the previous session.
European markets were mixed during mid-morning trade after hitting a 14-month high earlier in the session as investors digested key earnings reports.
Asia markets traded mostly higher, tracking U.S. gains, as investors await policy details from the Trump administration on tax reforms and deregulation.
Data docket: existing home sales for January at 10 a.m ET with the latest minutes from the FOMC meeting due to be released at 2 p.m ET.
The stem, cell, gene and regenerative therapy (SCG&RT) closed NEGATIVE on Tuesday, Monday was a holiday following a POSITIVE Friday, NEGATIVE Thursday and POSITIVE last Wednesday.
The SCG&RT sector’s record after the last 5 days (of 43 covered companies):
· Tuesday closed NEGATIVE with 21 decliners, 17 advancers and 5 flats;
· Monday, the market was closed;
· Friday closed POSITIVE with 17 decliners, 21 advancers and 5 flats;
· Thursday closed NEGATIVE with 26 decliners, 16 advancers and 1 flat;
· Last Wednesday closed POSITIVE with 15 decliners, 25 advancers and 3 flats;
Remembering Tuesday’s closing bell newsletter, “What are investors feeling? Forgotten is the answer!”
- Reiterating, “How many CEOs have forgotten the lifeblood of their share pricing – investors !
Bottom Line: an abuse of investor trust! It’s time to send a message …
- Right now, too many CEOs are using bad math and faulty logic to push their share pricing toward sustainability.
As shareholder’s equity falls further and further DOWN!
- Leadership is more than showing up for an oversized paycheck, CEOs are judged by their share pricing.
Companies are not above reproach and must be accountavle to investors!
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
· The iShares Nasdaq Biotechnology (IBB) closed Tuesday down -0.53% and is DOWN -0.30% in Wednesday’s pre-market;
· The SPDR S&P Biotech ETF (XBI) closed Tuesday down -0.63% and is NOT indicating in Wednesday’s after-market;
· The Health Care Select Sector SPDR ETF (XLV) closed up +0.45% Tuesday and NOT indicating in Wednesday’s pre-market;
· The iShares Russell 2000 (IWM) closed up +0.78% on Tuesday and is DOWN -0.43% in Wednesday’s pre-market
Companies in my headlights:
Biostage (BSTG) closed UP +$0.04 to $0.375 after Friday’s $0.335 after a $0.40 share offering that reaped a measly $8 M. - hopefully enough money to last them to next February but, they do have new offices and a brand new cafeteria costing $100 K that investors have just paid for with $0.30 stock. BSTG will stay under $0.40 as “bottom feeders” sell the stock and keep the warrants. Consider $0.25 or less as a resting spot IF an IND is still NOT finalized for submittal in Q3/17 – Who is kidding whom – there are no toasters being given away - Strong SELL;
bluebird bio (BLUE) closed down -$0.85 to $76.25. BLUE has been floating in a range, retracing and then diving again. The aftermarket indication was negative -$0.25 – SELL;
Organovo holdings (ONVO) closed UP +$0.03 to $3.00 after published data demonstrating that 3D bioprinted human kidney tissue has great potential to assess the toxic effects of compounds and the development and progression of complex, multicellular processes such as fibrosis. If cures are not in the mix utilization of tissues to test toxicity is the answer – Maintaining BUY;
Spark Therapeutics (ONCE) closed UP +$0.22 to $64.71 with financial results being announced before the opening bell. ONCE is very ripe for some profit taking after last week’s range bound closings. ONCE’s net loss applicable to common stockholders was $123.7 M, or ($4.29) basic and diluted net loss per common share, as compared with a net loss applicable to common stockholders of $47.8 M, or ($2.10) basic and diluted net loss per common share for the year. As of 12/31/16, ONCE had cash and cash equivalents and marketable securities of $318.1 M, which does not include the $15 M milestone payment ONCE received in January from Pfizer – BUY;
Verastem (VSTM) closed UP +$0.02 to $1.25 following Friday’s $1.23, Thursday’s $1.23 and last Wednesday’s $1.24. There is $86.88 M in cash in the till with total cash per share of $2.35 as of 9/31/16 – Maintaining BUY;
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.
